Persistence and baseline determinants of seropositivity in health care workers up to nine months after COVID-19

Carlota Dobaño (carlota.dobano@isglobal.org)
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona
https://orcid.org/0000-0002-6751-4060

Anna Ramirez
IDIAP Jordi Gol
https://orcid.org/0000-0001-8263-1292

Selena Alonso
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona
https://orcid.org/0000-0003-4029-9716

Josep Vidal-Alaball
Institut Català de la Salut
https://orcid.org/0000-0002-3527-4242

Gemma Ruiz-Olalla
ISGlobal

Marta Vidal
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona

Rocío Rubio
ISGlobal

Emma Cascant
ISGlobal

Daniel Parras
IDIBAPS
https://orcid.org/0000-0002-2677-4245

Natalia Rodrigo Melero
CRG

Pau Serra
IDIBAPS

Carlo Carolis
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona
https://orcid.org/0000-0003-4240-1139

Pere Santamaria
Faculty of Medicine, University of Calgary

Anna Forcada
Gerència territorial de Catalunya Central

Jacobo Mendioroz
ICS

Ruth Aguilar
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona
https://orcid.org/0000-0003-3277-3107

Gemma Moncunill
ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona
https://orcid.org/0000-0001-5105-9836

Anna Ruiz-Comellas
Brief Communication

Keywords: Antibody Responses, SARS-CoV-2, Primary Health Care Workers, Reinfection

DOI: https://doi.org/10.21203/rs.3.rs-142984/v1

License: © ① This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

We determined the duration and baseline determinants of antibody responses to SARS-CoV-2 up to nine months after COVID-19 symptoms onset in 173 primary health care worker patients from Spain. Seropositivity to SARS-CoV-2 spike and RBD antigens was 92.49% (60.69% IgM, 76.3% IgA, 90.17% IgG), with four suspected reinfection cases. Antibody levels significantly correlated with fever, hospitalization, anosmia/hypogeusia, allergies, smoking and occupation, and persisted 149-270 days in this cohort of patients.

Main Text

One of the key questions to understand the evolution of the COVID-19 pandemic is the duration of the immune response generated upon infection with SARS-CoV-2. Studies have shown that most patients induce a robust humoral and cellular response but with high heterogeneity and a percentage of non-responders. Diversity in epitope specificity, quality and functional capacity of antibodies will likely affect the efficacy of the immunity mediated. Although a number of cases of SARS-CoV-2 reinfection have been reported, antibodies were recently associated with protective immunity over a 30-week follow up. The spike (S) protein on the virus surface is considered the main target of protective antibodies, and the component of leading vaccine candidates. Functional neutralizing antibodies highly correlate with IgG levels to the receptor binding domain (RBD) of S, but IgA and IgM also have neutralizing properties, and non-neutralizing antibodies with Fc receptor-mediated functions are likely important for protective immunity.

Despite an increasing understanding of the nature of antibody responses, their longevity remains to be defined as the pandemic evolves. This is a critical question to predict whether the frequency of reinfection may increase if immunity wanes. As massive global immunization campaigns advance, this knowledge will give clues as to how long vaccine immunity may last and how preexisting antibodies and other baseline variables could affect vaccine effectiveness. Although some initial reports indicated a marked decline in antibodies after 3 months, subsequent studies have shown relatively stable antibody levels, mostly IgG, over a period of up to 6-8 months in small sets of patients.

We aimed to evaluate the seroprevalence and levels of antibodies 149-270 days after the onset of symptoms in a cohort of 173 primary health care workers (HCW) from 5 counties in Barcelona province, Spain, with COVID-19 at the first peak of the pandemic (March-April 2020) and being followed up for 1.5 years. HCW are at the forefront of this medical emergency and thus considered a high-risk population. The study protocol was approved by the IRB Comitè Étic d'Investigació Clínica IDIAP Jordi Gol (codes 20/094-PCV and 20/162-PCV) and written informed consent was obtained from participants.

Demographic and clinical data were collected to characterize the factors associated with disease presentation, presence of sequelae, long COVID-19 and reinfection in this cohort. Most cases were mild-moderate COVID-19, with 24 hospitalized, and 64 presenting with sequelae. Median age was 49 years (IQR 41-58) and 137 were females. Clinical information included history of previous allergies and smoking (13 smokers, 31 ex-smokers). Baseline symptoms recorded were fever, shivers, headache, asthenia, myalgia, arthralgia, dyspnea, chest pain, cough, sputum production, hemoptysis, anosmia, hypoageusia, odynophagia, tachycardia, dizziness and thrombosis. For the multivariable regression analysis, symptoms were grouped into categories: digestive (diarrhea, abdominal pain, nausea and/or vomiting, anorexia), otolaryngology (sneezing, rhinorrhea, nasal
obstruction, epistaxis, tinnitus, hearing loss), neurological (impaired consciousness, ataxia, acute cerebrovascular disease, seizures, neuralgia), ophthalmology (conjunctiva hyperemia, tearing, dry eyes, blurred vision), and skin disorders (rash, vesicular lesions, maculopapular lesions, itchy skin, pseudo pemiosis).

Three cross-sectional surveys were done between September and November 2020 to obtain venous blood for assessing maintenance of anti-SARS-CoV-2 seropositivity and analyze baseline factors associated with antibody levels. Levels of IgM, IgA and IgG to RBD and S recombinant proteins expressed from plasmids donated by F. Krammer (Mount Sinai, NY) were quantified in plasma by Luminex, as described\textsuperscript{11}. The cutoff for seropositivity was calculated with 55 pre-pandemic samples as 10 to the mean plus 3 standard deviations of log\textsubscript{10}-transformed mean fluorescence intensity values.

We did not detect a significant decline in antibody levels as a function of time since symptoms onset (Figure 1). The percentage of seropositivity 149-270 days after symptoms onset combining RBD and S antigens was 60.69\% for IgM, 76.30\% for IgA, and 90.17\% for IgG, consistent with the expected longer duration of the latter isotype. Unexpectedly, seropositivity was considerably sustained also for IgM and IgA, considered of shorter duration. Computing all immunoglobulin isotypes, seroprevalence 5-9 months after the initial COVID-19 episode was as high as 92.49\%, indicating highly stable persistence of responses.

There were four suspected reinfections (Table S1). Before the second positive PCR, two symptomatic cases were seronegative, one asymptomatic was seropositive with low antibodies, and one had unknown serostatus. Unfortunately, viral RNA was not available from the first episodes for genome sequencing and demonstration of different strains.

The baseline factors most consistently and significantly associated with higher levels of antibodies 5-9 months later in stepwise multivariable regression analyses were having been admitted to hospital, presenting with fever (n=131), anosmia and/or hypogeusia (n=106), and previous allergies (n=24) (Table 1). Specifically, for anti-S IgG, HCW with fever had 2.5 times higher levels, patients with anosmia and/or hypogeusia had 2.6 times higher levels, and those with allergies had 1.9 times higher levels, than patients without those conditions. Baseline factors associated with lower levels of IgA and IgG included being a nurse (n=68) or a physician (n=70) compared to other occupations (n=35), and smoking. For anti-S IgA, physicians had 34.84\% and nurses 45.67\% lower levels than the other jobs, and smokers had 46.17\% less than non-smokers (Table 1). Other factors were associated with only certain isotypes. Presenting with sputum and/or hemoptysis (n=13) was associated with higher IgM levels, and shivers (n=86) were associated with higher IgAs. Of note, hospitalized patients had 2.1 times higher IgM levels to RBD than non-hospitalized. Age correlated positively with IgGs, having 1.39\% higher antibody levels to RBD with each year of age older (Table 1). Higher IgGs (and IgAs less strongly) positively correlated with duration of symptoms (median 24 days, IQR 13-36; S rho=0.229 P=0.002; RBD rho=0.246, P=0.001) and number of symptoms (median 10, IQR 6-12; S rho=0.351 P<0.001; RBD rho=0.364, P<0.001). All other variables, symptoms, or sequelae, were either not statistically significantly associated with antibody levels or weakly in univariable models.

Previous acute phase studies showed that COVID-19 severity was associated with higher antibody responses. Here, hospitalization was associated with higher immunoglobulin levels many months after convalescence, suggesting that severity does not affect stability of memory B cell and plasma cells producing antibodies\textsuperscript{12}. Common symptoms like fever and highly specific symptoms like alteration in smell and taste were also associated with higher antibodies. Interestingly, having previous allergies also correlated positively with higher
antibody levels, which to our knowledge has not been reported. This could be related to disease exacerbation and increased risk of respiratory infections associated with some allergies\textsuperscript{13} although this relationship remains unclear. Lower antibody levels in nurses and physicians than other HCW could indicate a lower exposure due to PPE use and higher awareness of risks\textsuperscript{14}. Smoking had previously been associated with lower antibody responses\textsuperscript{15} and we show that this effect persists after several months primarily affecting IgA, the main mucosal antibody.

In conclusion, despite the large heterogeneity in antibody levels induced by SARS-CoV-2 infection, the majority of HCW patients remained seropositive for anti-S antibodies up to nine months after COVID-19. The findings that after PCR reversion, 2 out of 13 seronegatives had another symptomatic episode, and that one low responder had a second (asymptomatic) infection, are consistent with a protective role for antibodies\textsuperscript{2}. Data suggest that immune memory induced by first generation vaccines could also be long-lasting, therefore reducing the probability that periodical boosters might be required to sustain protective immunity.

**Declarations**

**Acknowledgements:** We thank the HCW for their participation in the study. We are grateful to Chenjerai Jairoce and Robert Mitchell for assistance with sample processing.

**Funding:** The study received support from the Fundació Privada Daniel Bravo Andreu. ISGlobal receives support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.

**Tables**

**Table 1.** Baseline variables associated with the levels of antibodies to SARS-CoV-2 spike antigens 5-9 months after COVID-19 symptoms onset by multivariable stepwise regression models.
| Predictors               | Spike  | Receptor binding domain |
|-------------------------|--------|-------------------------|
|                         | Beta   | 95%CI       | p-value | Beta | 95%CI     | p-value |
|                         |        |             |         |      |           |         |
| IgM^2                   | Hospitalization | 0.187 | 0.025 | 0.348 | 0.024 | 0.324 | 0.150 | 0.498 | <0.001 |
|                         | Previous allergies | 0.157 | 0.000 | 0.314 | 0.051 | ns   | ns    | ns    | ns    |
|                         | Sputum and/or hemoptysis | 0.156 | -0.050 | 0.363 | 0.137 | 0.268 | 0.047 | 0.489 | 0.018 |
|                         | Anosmia/hypogeusia | 0.108 | -0.003 | 0.220 | 0.057 | 0.091 | -0.028 | 0.210 | 0.133 |
|                         | Fever | 0.091 | -0.038 | 0.219 | 0.165 | 0.112 | -0.027 | 0.250 | 0.113 |
|                         | Digestive alterations | ns | ns | ns | ns | -0.089 | -0.210 | 0.033 | 0.152 |
| IgA                     | Fever | 0.250 | 0.094 | 0.406 | 0.002 | 0.178 | 0.060 | 0.296 | 0.003 |
|                         | Previous allergies | ns^4 | ns | ns | ns | 0.157 | 0.016 | 0.298 | 0.029 |
|                         | Hospitalization | ns | ns | ns | ns | 0.156 | 0.013 | 0.299 | 0.033 |
|                         | Shivers | 0.160 | 0.024 | 0.296 | 0.022 | 0.087 | -0.014 | 0.188 | 0.091 |
|                         | Anosmia/hypogeusia | 0.139 | 0.004 | 0.273 | 0.043 | ns   | ns    | ns    | ns    |
|                         | Smoking | -0.269 | -0.524 | -0.015 | 0.038 | -0.222 | -0.411 | -0.032 | 0.022 |
|                         | Nurses^5 | -0.265 | -0.443 | -0.086 | 0.004 | -0.223 | -0.357 | -0.090 | 0.001 |
|                         | Physicians^5 | -0.186 | -0.360 | -0.003 | 0.046 | -0.219 | -0.352 | -0.087 | 0.001 |
| IgG                     | Anosmia/hypogeusia | 0.413 | 0.258 | 0.568 | <0.001 | 0.189 | 0.077 | 0.301 | 0.001 |
|                         | Fever | 0.398 | 0.218 | 0.578 | <0.001 | 0.301 | 0.169 | 0.432 | <0.001 |
|                         | Previous allergies | 0.269 | 0.053 | 0.485 | 0.015 | 0.137 | -0.021 | 0.295 | 0.090 |
|                         | Hospitalization | 0.187 | -0.024 | 0.398 | 0.082 | 0.236 | 0.068 | 0.404 | 0.006 |
|                         | Age | 0.007 | 0.000 | 0.014 | 0.050 | 0.006 | 0.001 | 0.011 | 0.023 |
|                         | Cough | 0.124 | -0.034 | 0.283 | 0.123 | ns   | ns    | ns    | ns    |
|                         | Digestive alterations | ns | ns | ns | ns | 0.088 | -0.025 | 0.202 | 0.126 |
|                         | Smoking | -0.295 | -0.580 | -0.009 | 0.043 | ns   | ns    | ns    | ns    |
|                         | Nurses | ns | ns | ns | ns | -0.187 | -0.335 | -0.039 | 0.014 |
|                         | Physicians | ns | ns | ns | ns | -0.105 | -0.253 | 0.042 | 0.159 |

^1Estimate of the model (beta coefficient). A transformed beta value (%) of the log-linear model can be calculated with the formula: ((10^beta)-1)*100, giving the difference (in percentage) in antibody levels when comparing to the reference group for categorical variables or for a one-unit change for continuous variables (see text for interpretation). ^2log_{10}MFI: logarithm 10 median fluorescent intensity (antibody levels). ^3CI: confidence interval of
the model estimate (beta). 4ns: not significant (not retained in the stepwise forward/backward multivariable model). 5Nurses (n=68) include 8 auxiliary nurses, and physicians (n=70) include 1 dentist. Both are compared to other occupational categories working in primary health care centers including customer and social services staff (n=35).

Supplementary Information

Table S1. Characteristics of the suspected SARS-CoV-2 reinfection cases.

| Socio demographics | First COVID-19 episode | Second COVID-19 episode | Serology |
|--------------------|------------------------|-------------------------|----------|
|                     | Symptoms¹ | PCR | Symptoms | PCR |
| Female 29 yr nurse  | March 15ᵗʰ - May 14ᵗʰ | Positive: April 2ⁿᵈ | October 13ᵗʰ - December 23ʳᵈ | Positive: October 13ᵗʰ | Seronegative September / Seroconverted October |
| Female 41 yr physician | March 24ᵗʰ - May 4ᵗʰ | Positive: March 27ᵗʰ | August - May 4ᵗʰ (Jan 2021) | Positive: August 2⁵ᵗʰ September / Seroconverted September |
| Female 58 yr administrative | March 23ʳᵈ - March 25ᵗʰ | Positive: March 2³ʳᵈ | May 2⁰ᵗʰ  - May 2¹ⁿˢᵗ,  June 4ᵗʰ | Unknown April / Seropositive November |
| Female 44 yr physician | March 2³ʳᵈ - April 3ʳᵈ | Positive: March 2⁵ᵗʰ | No symptoms | Positive²: November 1⁹ᵗʰ | Seropositive³ September |

¹Date of start and end of the first and last symptoms. All dates are 2020 unless otherwise indicated.

²PCR was done prior to a surgical procedure and not as part of a routine screening, the participant had no symptoms.

³Low level antibody responses above the seropositivity threshold.
References

1. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science (80-)*. 2020;370(6521):1227 LP - 1230. doi:10.1126/science.abd7728

2. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med*. December 2020. doi:10.1056/NEJMoa2034545

3. Krammer F. SARS-CoV-2 vaccines in development. *Nature*. 2020;586(7830):516-527. doi:10.1038/s41586-020-2798-3

4. Klingler J, Weiss S, Itri V, et al. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. *medRxiv*. January 2020:2020.08.18.20177303. doi:10.1101/2020.08.18.20177303

5. Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol*. 2020;5(12):1598-1607. doi:10.1038/s41564-020-00813-8

6. Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. *Immunity*. 2020;53(5):925-933.e4. doi:10.1016/j.immuni.2020.10.004

7. Liu C, Yu X, Gao C, et al. Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients. *J Med Virol*. November 2020. doi:10.1002/jmv.26646

8. Chen Y, Zuiani A, Fischinger S, et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. *Cell*. November 2020. doi:10.1016/j.cell.2020.10.051

9. Choe PG, Kim K-H, Kang CK, et al. Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection. *Emerg Infect Dis*. 2020;27(3). doi:10.3201/eid2703.204543

10. Figueiredo-Campos P, Blankenhaus B, Mota C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. *Eur J Immunol*. 2020;50(12):2025-2040. doi:10.1002/eji.202048970

11. Dobaño C, Vidal M, Santano R, et al. Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens. *J Clin Microbiol*. January 2020:DOI: 10.1101/2020.06.11.147363. doi:10.1101/2020.06.11.147363

12. Hartley GE, Edwards ESJ, Aui PM, et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. *Sci Immunol*. 2020;5(54):eabf8891. doi:10.1126/sciimmunol.abf8891

13. Yang JM, Koh HY, Moon SY, et al. Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study. *J Allergy Clin Immunol*. October 2020. doi: 10.1016/j.jaci.2020.08.008

14. Moncunill G, Mayor A, Santano R, et al. SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up. *J Infect Dis*. 2021 Jan 4;223(1):62-71. doi: 10.1093/infdis/jiaa696

15. Schaffner A, Risch L, Aeschbacher S, et al. Characterization of a Pan-Immunoglobulin Assay Quantifying Antibodies Directed against the Receptor Binding Domain of the SARS-CoV-2 S1-Subunit of the Spike Protein: A Population-Based Study. *J Clin Med*. 2020;9(12). doi:10.3390/jcm9123989

Figures
Figure 1

Antibody levels by days since COVID-19 symptoms onset.